Kidney Disease Clinical Trials

Showing 2741-2760 of 3,902 trials

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

NCT01829841

* Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. * The purpose of this study is to compare the efficacy and safety profile between Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.

Renal Cell CancerMetastatic Renal Cell Cancer

Jiangsu HengRui Medicine Co., Ltd.150 participantsStarted May 2011

Beijing, China

COMPLETEDPhase 3

Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia

NCT01095939

The purpose of the Post-preeclampsia Renal Project is to investigate the renal function of preeclamptic women after delivery, and to determine whether the anti-hypertensive drug named benazepril efficiently improves the dysfunctions observed.

Renal Alteration

University Hospital, Geneva120 participantsStarted Apr 2010

Geneva, Switzerland • Lausanne, Switzerland

COMPLETEDPhase 1

Study Of Palbociclib (PD-0332991) In Renal Impairment

NCT02085538

Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function.

Renal Impairment

Pfizer31 participantsStarted May 2014

DeLand, Florida, United States • Orlando, Florida, United States • Saint Paul, Minnesota, United States

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia

Study Of Palbociclib (PD-0332991) In Renal Impairment

Related Searches

Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

Evaluation of the Muscular and Cutaneous Sodium Storage by 23Na MRI in Patients With Chronic Adrenal Insufficiency

Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)

Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization

Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis

Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects

Study to Investigate Adrenal Crisis (Six-year Follow-up)

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

Accelerated Immunosenescence and Chronic Kidney Disease

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Female Sexual Dysfunctions in Chronic Kidney Disease

Cost Utility Analysis of HD and CAPD in Ministry of Health Dialysis Centres, Malaysia

The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial

Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study